LDN for MS—University of California, San Francisco
A study of LDN in the treatment
of MS at the University of California, San Francisco
, was implemented in early 2007 by neurological researcher Bruce Cree, MD, and colleagues. Some 80 patients with MS were involved in this double-blind, “Randomized, Placebo-Controlled, Crossover-Design Study of the Effects of Low Dose Naltrexone on Quality of Life as Measured by the Multiple Sclerosis Quality of Life Inventory.